AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32458554 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 58
Study 32458554 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 58
Study 32827269 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 20
Study 32827269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 35679057 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) using Oculus Quest headset
Number of subjects: 29
Study 35679057 — intervention group
Group type: COMPARATOR
Intervention: Control using handheld smartphone device
Number of subjects: 29
Study 32734504 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-months web-based intensive prevention program
Number of subjects: 0
Study 32734504 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 32734504 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intensive prevention program with genetic risk disclosure
Number of subjects: 0
Study 32734504 — intervention group
Group type: COMPARATOR
Intervention: Web-based intensive prevention program without genetic risk disclosure
Number of subjects: 0
Study 34456847 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonbridge stent
Number of subjects: 220
Study 34456847 — intervention group
Group type: COMPARATOR
Intervention: Solitaire FR
Number of subjects: 220
Study 35914257 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application for self-managing a FODMAP-lowering diet
Number of subjects: 0
Study 35914257 — intervention group
Group type: COMPARATOR
Intervention: Otilonium bromide
Number of subjects: 0
Study 33427305 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID
Number of subjects: 5136
Study 33378508 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-extraction group (DEG)
Number of subjects: 32
Study 33378508 — intervention group
Group type: COMPARATOR
Intervention: Single-extraction group (SEG)
Number of subjects: 32
Study 36287379 — intervention group
Group type: EXPERIMENTAL
Intervention: RBX2660
Number of subjects: 289
Study 36287379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 33928755 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple mobile health devices (Fitbit Alta® fitness tracker, iHealth® glucometer, BodyTrace® scale)
Number of subjects: 20
Study 33928755 — intervention group
Group type: EXPERIMENTAL
Intervention: Visualizations generated from health data obtained from the three devices
Number of subjects: 20
Study 36149770 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (VITC; ∼2‐3 g)
Number of subjects: 27
Study 36149770 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral BH4 (KUVAN, 10 mg/kg body wt)
Number of subjects: 27
Study 36149770 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of VITC + BH4
Number of subjects: 27
Study 36149770 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 27
Study 33724103 — intervention group
Group type: EXPERIMENTAL
Intervention: PASTA intervention
Number of subjects: 1214
Study 33724103 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1214
Study 36074201 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health intervention
Number of subjects: 50
Study 36074201 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 50
Study 33517804 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Carnitine (3000 mg daily until ovulation)
Number of subjects: 83
Study 33517804 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 83
Study 33517804 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Carnitine
Number of subjects: 83
Study 34818686 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD) for 6 weeks with diet counselling
Number of subjects: 42
Study 34818686 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 42
Study 33942065 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group B (EG B) - application of the primer and Brief Motivational Interviewing (BMI)
Number of subjects: 181
Study 33942065 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group A (EG A) - who read the primer
Number of subjects: 181
Study 33942065 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 181
Study 32874108 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump training (twice-weekly for 8 weeks)
Number of subjects: 126
Study 32874108 — intervention group
Group type: COMPARATOR
Intervention: Control (regular physical education lessons)
Number of subjects: 126
Study 36263002 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate (RB) combined with alfentanil (10 μg/Kg alfentanil + RB 0.2 mg/kg intravenously)
Number of subjects: 0
Study 36263002 — intervention group
Group type: COMPARATOR
Intervention: Propofol combined with alfentanil (10 μg/Kg alfentanil + propofol 1.5 mg/kg)
Number of subjects: 0
Study 36263002 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate (RB) combined with alfentanil
Number of subjects: 0
Study 36263002 — intervention group
Group type: COMPARATOR
Intervention: Propofol combined with alfentanil
Number of subjects: 0
Study 34246485 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan (200 mg) under fasting condition
Number of subjects: 24
Study 34246485 — intervention group
Group type: COMPARATOR
Intervention: Tegoprazan (200 mg) under fed condition
Number of subjects: 24
Study 34954448 — intervention group
Group type: EXPERIMENTAL
Intervention: Expand Your Horizon (n = 72)
Number of subjects: 135
Study 34954448 — intervention group
Group type: COMPARATOR
Intervention: Active control condition (expressive writing, n = 63)
Number of subjects: 135
Study 33229756 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant EPO Beta (Recormon) administered via subcutaneous route in weekly doses of 2000 IU, 4000 IU, 6000 IU, 8000 IU, 12,000 IU, or 18,000 IU according to the severity of anemia.
Number of subjects: 40
Study 33229756 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group).
Number of subjects: 40
Study 35089798 — intervention group
Group type: COMPARATOR
Intervention: Intensive blood pressure treatment
Number of subjects: 2466
Study 35089798 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure treatment
Number of subjects: 2466
Study 32660811 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic recommendation for treatment of abnormal infant heads based on perceived deformity severity.
Number of subjects: 395
Study 32660811 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized photographs of children with positional cranial deformities presented to laypeople.
Number of subjects: 395
Study 32660811 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference values for cranial index and cranial vault asymmetry index.
Number of subjects: 395
Study 35253334 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone <15 mg/day
Number of subjects: 1938
Study 35253334 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg/day and 30 mg/day (pooled)
Number of subjects: 1938
Study 35253334 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg/day
Number of subjects: 1938
Study 35253334 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg/day
Number of subjects: 1938
Study 35253334 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg/day
Number of subjects: 1938
Study 35253334 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone <45 mg/day
Number of subjects: 1938
Study 35253334 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (all doses)
Number of subjects: 1938
Study 35253334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1938
Study 33964301 — intervention group
Group type: EXPERIMENTAL
Intervention: Subphenotype 1 (SP1) characterized by shock, acidemia, and multiorgan dysfunction.
Number of subjects: 3300
Study 33964301 — intervention group
Group type: EXPERIMENTAL
Intervention: Subphenotype 2 (SP2) characterized by high C-reactive protein and early need for mechanical ventilation.
Number of subjects: 3300
Study 33964301 — intervention group
Group type: EXPERIMENTAL
Intervention: Subphenotype 3 (SP3) showing the highest burden of chronic diseases.
Number of subjects: 3300
Study 33964301 — intervention group
Group type: COMPARATOR
Intervention: Subphenotype 4 (SP4) demonstrating limited chronic disease burden and mild physiologic abnormalities.
Number of subjects: 3300
Study 34085151 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan training (12 weeks)
Number of subjects: 23
Study 34085151 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 23
Study 33876230 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral (DAA) treatment
Number of subjects: 113
Study 33890515 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 49
Study 33890515 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 49
Study 33986479 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID pre-operative administration (Ibuprofen)
Number of subjects: 56
Study 33986479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 32812384 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil group (EPA-rich fish oil: 600 mg EPA and 260 mg DHA per day for 8 weeks)
Number of subjects: 19
Study 32812384 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (matching capsules for the same duration)
Number of subjects: 19
Study 32812384 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil group
Number of subjects: 19
Study 32812384 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 19
Study 35655285 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornerstone intervention (lay navigator-led, early palliative care coaching)
Number of subjects: 294
Study 35655285 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 294
Study 34786904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine G-CSF injections
Number of subjects: 150
Study 34786904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine hCG injections (500 IU)
Number of subjects: 150
Study 34786904 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine saline solution (placebo)
Number of subjects: 150
Study 33350660 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard training with a mental health awareness module
Number of subjects: 418
Study 33350660 — intervention group
Group type: COMPARATOR
Intervention: Standard training
Number of subjects: 418
Study 34169558 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental caries
Number of subjects: 539
Study 34169558 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontitis
Number of subjects: 539
Study 34169558 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental anxiety
Number of subjects: 539
Study 34169558 — intervention group
Group type: EXPERIMENTAL
Intervention: Halitosis
Number of subjects: 539
Study 33824113 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% metronidazole gel
Number of subjects: 3
Study 33824113 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% metronidazole mouthwash
Number of subjects: 3
Study 33824113 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 3
Study 35580701 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (target plasma concentration 100 ng/mL)
Number of subjects: 0
Study 35580701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35580701 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 0
Study 33534267 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-protective group (5 cmH2O positive end-expiratory pressure and recruitment manoeuvres every 30 minutes)
Number of subjects: 60
Study 33534267 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-protective group
Number of subjects: 60
Study 33534267 — intervention group
Group type: COMPARATOR
Intervention: Control group (zero end-expiratory pressure with no recruitment manoeuvres)
Number of subjects: 60
Study 33534267 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 33235184 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (20 mg/day for 3 months)
Number of subjects: 4
Study 33235184 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of leflunomide and everolimus
Number of subjects: 4
Study 36056369 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diazepam before the operation
Number of subjects: 180
Study 36056369 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo before the operation
Number of subjects: 180
Study 34602464 — intervention group
Group type: EXPERIMENTAL
Intervention: Active HD-tDCS (2mA for 20 minutes)
Number of subjects: 32
Study 34602464 — intervention group
Group type: COMPARATOR
Intervention: Sham HD-tDCS
Number of subjects: 32
Study 32816830 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre-fix supplement added to a low FODMAP diet
Number of subjects: 0
Study 32816830 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 33999741 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid Treatment Programs (OTP) in inpatient treatment
Number of subjects: 0
Study 33999741 — intervention group
Group type: COMPARATOR
Intervention: Opioid Treatment Programs (OTP)
Number of subjects: 0
Study 34881557 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi intervention for 12 weeks
Number of subjects: 99
Study 34881557 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal dietary and exercise habits)
Number of subjects: 99
Study 35479188 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin combined with meglumine adenosine cyclophosphate
Number of subjects: 100
Study 35479188 — intervention group
Group type: COMPARATOR
Intervention: Meglumine adenosine cyclophosphate only
Number of subjects: 100
Study 32040591 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B (PMB)
Number of subjects: 160
Study 32040591 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 160
Study 32040591 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein lipase (LPL) treatment
Number of subjects: 160
Study 35998256 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavier-load resistance training (HL; 80% 1RM)
Number of subjects: 130
Study 35998256 — intervention group
Group type: EXPERIMENTAL
Intervention: Lighter-load resistance training (LL; 60% 1RM)
Number of subjects: 130
Study 35998256 — intervention group
Group type: COMPARATOR
Intervention: Comparison of HL and LL
Number of subjects: 130
Study 33478400 — intervention group
Group type: EXPERIMENTAL
Intervention: PerStBiRo training (N=7)
Number of subjects: 13
Study 33478400 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=6)
Number of subjects: 13
Study 33478400 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 13
Study 32014033 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel Integrated Care Concept (NICC)
Number of subjects: 964
Study 32014033 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 964
Study 34184544 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resistance inspiratory muscle strength training (IMST) (30 breaths/day, 6 days/week, 75% maximal inspiratory pressure)
Number of subjects: 36
Study 34184544 — intervention group
Group type: COMPARATOR
Intervention: Low-resistance sham training (15% maximal inspiratory pressure)
Number of subjects: 36
Study 32605585 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based mental health care programme GBV
Number of subjects: 1000
Study 33564887 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based therapeutic sailing (MBTS); three-session intervention combining nature exposure and mindfulness training.
Number of subjects: 25
Study 33860830 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps tendon tears involving the rectus femoris (RF) or vastus lateralis/vastus medialis (VL/VM) layers
Number of subjects: 52
Study 33860830 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of bony avulsion on radiographs
Number of subjects: 52
Study 33860830 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-reader reliability of MRI evaluations
Number of subjects: 52
Study 33860830 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaps in retracted torn tendons
Number of subjects: 52
Study 32624575 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 0
Study 32624575 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33710353 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative cleaning and disinfection of the NAC
Number of subjects: 129
Study 33710353 — intervention group
Group type: COMPARATOR
Intervention: No skin treatment before surgery (Control)
Number of subjects: 129
Study 32770686 — intervention group
Group type: EXPERIMENTAL
Intervention: I&D with LOOP technique
Number of subjects: 217
Study 32770686 — intervention group
Group type: COMPARATOR
Intervention: I&D with packing technique
Number of subjects: 217
Study 35460853 — intervention group
Group type: COMPARATOR
Intervention: Type of anesthesia administered
Number of subjects: 107
Study 35460853 — intervention group
Group type: COMPARATOR
Intervention: Complications
Number of subjects: 107
Study 33196931 — intervention group
Group type: EXPERIMENTAL
Intervention: Wielding a gun
Number of subjects: 0
Study 33196931 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 34231532 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment for severe ROP
Number of subjects: 0
Study 34231532 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF treatment (bevacizumab) for severe ROP
Number of subjects: 0
Study 34231532 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF treatment (bevacizumab)
Number of subjects: 0
Study 34231532 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 0
Study 34231532 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF treatment
Number of subjects: 0
Study 32312727 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrosurgical debridement ± decellularised dermal allograft, or combination with negative pressure wound therapy, as an adjunct to treatment as usual (TAU)
Number of subjects: 447
Study 32312727 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 447
Study 32312727 — intervention group
Group type: EXPERIMENTAL
Intervention: One treatment strategy continued from phase II
Number of subjects: 447
Study 32312727 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary objectives include healing status of the index ulcer, infection rate, reulceration, quality of life, cost-effectiveness, and incidence of adverse events
Number of subjects: 447
Study 36191310 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 0
Study 36191310 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or standard treatment not specified)
Number of subjects: 0
Study 34488853 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted Cognitive Behavioural Therapy (CaCBT)
Number of subjects: 0
Study 34488853 — intervention group
Group type: COMPARATOR
Intervention: Standard Cognitive Behavioural Therapy (CBT)
Number of subjects: 0
Study 32460790 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg GBS
Number of subjects: 18
Study 32460790 — intervention group
Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 18
Study 32460790 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg GBS
Number of subjects: 18
Study 36262074 — intervention group
Group type: EXPERIMENTAL
Intervention: Rota-Cut
Number of subjects: 110
Study 36262074 — intervention group
Group type: COMPARATOR
Intervention: Modified Balloon (MB)
Number of subjects: 110
Study 36262074 — intervention group
Group type: COMPARATOR
Intervention: Rotational Atherectomy (RA)
Number of subjects: 110
Study 33966113 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesotherapy (intra‐mucosal injection of ascorbic acid, 1/week for 3 weeks)
Number of subjects: 20
Study 33966113 — intervention group
Group type: COMPARATOR
Intervention: Topical gel (topical ascorbic acid gel, 1/day for 3 months)
Number of subjects: 20
Study 33966113 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 35288066 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg) every 2 weeks for ≤1 year
Number of subjects: 709
Study 35288066 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 2 weeks for ≤1 year
Number of subjects: 709
Study 32576090 — intervention group
Group type: EXPERIMENTAL
Intervention: TASK-CBT (n=14)
Number of subjects: 27
Study 32576090 — intervention group
Group type: COMPARATOR
Intervention: TASK-Relax (n=13)
Number of subjects: 27
Study 37910474 — intervention group
Group type: EXPERIMENTAL
Intervention: Biophilic virtual classroom environments
Number of subjects: 30
Study 37910474 — intervention group
Group type: COMPARATOR
Intervention: Control virtual classroom environments (non-biophilic)
Number of subjects: 30
Study 33205670 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive hypertension management approach
Number of subjects: 60
Study 33205670 — intervention group
Group type: COMPARATOR
Intervention: Traditional wellness practices
Number of subjects: 60
Study 35660387 — intervention group
Group type: EXPERIMENTAL
Intervention: Original Gymnastics for Pregnant Women program
Number of subjects: 131
Study 35660387 — intervention group
Group type: COMPARATOR
Intervention: Conventional intervention (Control)
Number of subjects: 131
Study 35660387 — intervention group
Group type: EXPERIMENTAL
Intervention: Original Gymnastics for Pregnant Women program (with lower exercise frequency)
Number of subjects: 131
Study 35660387 — intervention group
Group type: EXPERIMENTAL
Intervention: Original Gymnastics for Pregnant Women program (with reasonable exercise frequency)
Number of subjects: 131
Study 34425471 — intervention group
Group type: EXPERIMENTAL
Intervention: Hua Shi Bai Du Granule (Q-14) plus standard care
Number of subjects: 204